Newsinc24 Team 
Biological E Limited's Corbevax vaccine, India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19, has received emergency use authorisation (EUA) from India's drug regulator for the 12 to 18 years age group.Corbevax will be administered in two doses. Till now India has been administering Bharat Biotech's Covaxin to teens between 15 and 18 years old since January 3.
Corbevax is being billed as India's first homegrown "receptor-binding domain protein sub-unit vaccine against COVID-19". A receptor-binding d Corbevax will be administered in two dosesomain is a key part of a virus located on its "spike" domain that allows it to dock to body receptors to enter and infect cells. These are also the primary targets in the prevention and treatment of viral infections. "We are pleased with this significant development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country. We truly believe that with this approval, we are even more closer to finishing our global fight against the COVID-19 pandemic," Biological E Managing Director Mahima Datla said in a statement.
Related Posts
Drug abuse among children must be seen as child protection issue: CJI
Nearly 25 children dead in Gujarat as Chandipura virus returns
France becomes the first EU country to ban social media for children